Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Profit After Tax (2022 - 2025)

Historic Profit After Tax for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $42.0 million.

  • Indivior Pharmaceuticals' Profit After Tax rose 9090.91% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $128.0 million, marking a year-over-year increase of 22000.0%. This contributed to the annual value of $7.0 million for FY2024, which is 10555.56% up from last year.
  • According to the latest figures from Q3 2025, Indivior Pharmaceuticals' Profit After Tax is $42.0 million, which was up 9090.91% from $18.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Profit After Tax registered a high of $61.0 million during Q1 2024, and its lowest value of -$183.0 million during Q4 2022.
  • For the 4-year period, Indivior Pharmaceuticals' Profit After Tax averaged around $1.6 million, with its median value being $40.0 million (2022).
  • The largest annual percentage gain for Indivior Pharmaceuticals' Profit After Tax in the last 5 years was 12950.82% (2023), contrasted with its biggest fall of 42926.83% (2023).
  • Indivior Pharmaceuticals' Profit After Tax (Quarter) stood at -$183.0 million in 2022, then surged by 129.51% to $54.0 million in 2023, then plummeted by 61.11% to $21.0 million in 2024, then surged by 100.0% to $42.0 million in 2025.
  • Its Profit After Tax was $42.0 million in Q3 2025, compared to $18.0 million in Q2 2025 and $47.0 million in Q1 2025.